Latest Breaking News On - World cancer research fund international - Page 11 : vimarsana.com

Quibim Adds Cancer Detection Capability to Prostate AI Product

Quibim announced it has added an industry-leading cancer detection capability to its prostate tool based on artificial intelligence (AI). The updated product, QP-Prostate, which uses algorithms trained on actual pathology data as ground truth, has been given a CE mark for the European Union and a UKCA mark for the United Kingdom.

United kingdomDavid bazagaAngel alberich bayarriCancer research united kingdomEuropean unionWorld cancer research fund internationalMedical devicesNew yorkUnited states

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

France generalUnited statesSan franciscoChristelle huguetIpsen euronextEuropean medicines agencyOno pharmaceutical coAmerican cancer societyTakeda pharmaceutical company limitedAmerican society of clinical oncology genitourinary symposiumWorld cancer research fund internationalHead of researchEuropean unionBristol myers squibbTakeda pharmaceutical companyTranslational research unit at georges pompidou hospital

Ipsen Pharma: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

Ipsen Pharma: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalSan franciscoUnited statesChristelle huguetStefan klotterIpsen euronextAmerican society of clinical oncology genitourinary symposiumTakeda pharmaceutical company limitedTranslational research unit at georges pompidou hospitalEuropean unionAmerican cancer societyEuropean medicines agencyHead of researchWorld cancer research fund internationalAmerican societyClinical oncology genitourinary symposium

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

France generalSan franciscoUnited statesChristelle huguetIpsen euronextEuropean medicines agencyOno pharmaceutical coAmerican cancer societyTakeda pharmaceutical company limitedAmerican society of clinical oncology genitourinary symposiumWorld cancer research fund internationalHead of researchEuropean unionBristol myers squibbTakeda pharmaceutical companyTranslational research unit at georges pompidou hospital

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Issuer: Mainz BioMed N.V. / Key word(s): Conference11.01.2024 / 14:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology SymposiumBERKELEY, US – MAINZ, Germany – January 11, 2024 Mainz Biomed N.V. (NASDAQ:M.

United statesAgnieszka dobrowolskaHershel berrySteve quinnAnne hennecke caroline bergmannTomasz marekMainz biomedWorld cancer research fund internationalUs preventive services taskExchange commissionHotel radissonBlueprint life science groupMc servicesInternational business developmentPanel discussionDistribution services